4 news items
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
BMY
CATX
LNTH
15 May 24
) for imaging and alpha-particle targeted therapies using 212Pb. Preclinical studies are ongoing to assess whether this new molecular entity
Evaluating Lantheus Holdings: Insights From 5 Financial Analysts
LNTH
3 May 24
.
Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
BMY
CATX
LNTH
28 Mar 24
feasibility assessments on additional sites.Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third
Assessing Lantheus Holdings: Insights From 4 Financial Analysts
LNTH
23 Feb 24
0
In the assessment of 12-month price targets, analysts unveil insights for Lantheus Holdings, presenting an average
- Prev
- 1
- Next